Introduction to Bladder Cancer Type and Therapy

  • Sanchia S. GoonewardeneEmail author
  • Raj Persad
  • Hanif Motiwala
  • David Albala


Bladder cancer is a heterogeneous disease with a variable natural history. 70% present with NMI tumours (stages Ta, T1, or carcinoma in situ) (Sun and Trinh in Hematol Oncol Clin North Am 29(2):205–18, 2015). 30% present with muscle-invasive disease (T2–4) associated with a high risk of death from distant metastases (Sun and Trinh in Hematol Oncol Clin North Am 29(2):205–18, 2015). This chapter covers introduction to bladder cancer type and therapy.


  1. Amin MB, McKenney JK, Paner GP, Hansel DE, Grignon DJ, Montironi R, Lin O, Jorda M, Jenkins LC, Soloway M, Epstein JI, Reuter VE. ICUD-EAU international consultation on bladder cancer 2012: pathology. Eur Urol. 2013;63(1):16–35.CrossRefGoogle Scholar
  2. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10(6):311–22.CrossRefGoogle Scholar
  3. Sun M, Trinh QD. Diagnosis and staging of bladder cancer. Hematol Oncol Clin North Am. 2015;29(2):205–18, vii.CrossRefGoogle Scholar
  4. Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778–92.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Sanchia S. Goonewardene
    • 1
    Email author
  • Raj Persad
    • 2
  • Hanif Motiwala
    • 3
  • David Albala
    • 4
  1. 1.East of England DeaneryNorfolk and Norwich University HospitalNorwichUK
  2. 2.North Bristol NHS TrustBristolUK
  3. 3.Southend University HospitalWestcliff-on-SeaUK
  4. 4.Boston UniversityBostonUSA

Personalised recommendations